Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Bioavailability Study Design: Single Versus Multiple Dose Studies

Bioavailability Study Design: Single Versus Multiple Dose Studies

Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...

Measurement of Bioavailability: Pharmacodynamic Methods

Measurement of Bioavailability: Pharmacodynamic Methods

Pharmacodynamic methods provide insights into a drug's effects on physiological processes over time and play a crucial role in understanding bioavailability and therapeutic efficacy. These methods can be broadly classified into acute pharmacological and therapeutic response approaches, each with distinct mechanisms and applications.The acute pharmacological response method directly correlates a drug's physiological effects, such as ECG or pupil diameter changes, to its time course in the body.

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...

Measurement of Bioavailability: Pharmacokinetic Methods

Measurement of Bioavailability: Pharmacokinetic Methods

Pharmacokinetics is a vital branch of pharmacology that examines how drugs are absorbed, distributed, metabolized, and excreted by the body. Two key methodologies in pharmacokinetics are plasma drug concentration studies and urinary drug excretion analyses, both of which provide critical insights into a drug's therapeutic efficacy and bioavailability.Plasma Drug Concentration-Time StudiesPlasma drug concentration-time studies involve analyzing blood samples at specific intervals to quantify...

Modified-Release Drug Delivery Systems: Bioavailability

Modified-Release Drug Delivery Systems: Bioavailability

Modified-release (MR) dosage forms are designed to extend drug release over time, thereby maintaining stable plasma concentrations and reducing dosing frequency. However, their bioavailability is typically below 100% due to incomplete drug release and presystemic metabolism, and limitations in drug permeability across the gastrointestinal epithelium, all of which can restrict the fraction of the drug reaching systemic circulation. Consequently, studying the in vivo bioavailability of MR...

Drug Concentrations: Measurements

Drug Concentrations: Measurements

Drug concentration is the quantity of a drug present in a biological sample. Measuring drug amounts in biological samples allows the clinician to understand how a drug is absorbed, distributed, metabolized, and excreted. Samples can be obtained through invasive or non-invasive methods. Invasive techniques involve surgical or parenteral interventions to gather blood, cerebrospinal fluid, or tissue biopsy. Conversely, non-invasive approaches provide samples like urine, feces, and saliva.
Plasma —...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Evaluation of dose linearity in the systemic availability and pharmacokinetics of topically administered diclofenac: A <sup>14</sup>C-microdosing study in healthy volunteers.

Drug metabolism and disposition: the biological fate of chemicals·2025

Same author

Accelerator mass spectrometry for quantification of micro- and therapeutic-dose diclofenac in microdialysis samples.

Bioanalysis·2022

Same author

An Investigation of the Metabolism and Excretion of KD101 and Its Interindividual Differences: A Microtracing Mass Balance Study in Humans.

Clinical and translational science·2021

Same author

Human ADME for YH12852 using wavelength scanning cavity ring-down spectroscopy (WS-CRDS) after a low radioactivity dose.

Bioanalysis·2020

Same author

Adverse outcome pathway of developmental neurotoxicity resulting from prenatal exposures to cannabis contaminated with organophosphate pesticide residues.

Reproductive toxicology (Elmsford, N.Y.)·2019

Same author

Nanotracing and cavity-ring down spectroscopy: A new ultrasensitive approach in large molecule drug disposition studies.

PloS one·2018

Search research articles

Related Experiment Video

Updated: Jun 6, 2026

Hippocampal Insulin Microinjection and In vivo Microdialysis During Spatial Memory Testing

Hippocampal Insulin Microinjection and In vivo Microdialysis During Spatial Memory Testing

Published on: January 11, 2013

Early human ADME using microdoses and microtracers: bioanalytical considerations.

Stephen R Dueker¹, Peter N Lohstroh, Jason A Giacomo

¹Vitalea Science Inc., 2121 Second Street, B101 Davis, CA 95618, USA. srdueker@vitaleascience.com

|November 19, 2010

Summary

This summary is machine-generated.

Accelerator mass spectrometry enables sensitive detection of carbon-14 (14C) drug metabolites using lower radioactivity doses. This advance facilitates early-stage drug development by improving the quantification of drug metabolism and disposition in humans.

More Related Videos

Multi-Tracer Studies of Brain Oxygen and Glucose Metabolism Using a Time-of-Flight Positron Emission Tomography-Computed Tomography Scanner

Multi-Tracer Studies of Brain Oxygen and Glucose Metabolism Using a Time-of-Flight Positron Emission Tomography-Computed Tomography Scanner

Published on: June 7, 2024

Related Experiment Videos

Last Updated: Jun 6, 2026

Hippocampal Insulin Microinjection and In vivo Microdialysis During Spatial Memory Testing

Hippocampal Insulin Microinjection and In vivo Microdialysis During Spatial Memory Testing

Published on: January 11, 2013

Multi-Tracer Studies of Brain Oxygen and Glucose Metabolism Using a Time-of-Flight Positron Emission Tomography-Computed Tomography Scanner

Multi-Tracer Studies of Brain Oxygen and Glucose Metabolism Using a Time-of-Flight Positron Emission Tomography-Computed Tomography Scanner

Published on: June 7, 2024

Area of Science:

Pharmacokinetics and Drug Metabolism
Analytical Chemistry
Radiopharmaceutical Science

Background:

Quantitative assessment of drug metabolites in early development is challenging due to the lack of available methods and standards.
Radiocarbon ((14)C) labeling is crucial for metabolite quantification but traditional detection methods require high radioactivity doses, limiting early use.
High doses and costs associated with (14)C tracers have historically hindered routine application in drug metabolism and disposition studies.

Purpose of the Study:

To introduce Accelerator Mass Spectrometry (AMS) as a solution for sensitive metabolite quantification in early-phase drug development.
To describe empirically based approaches for regulated bioanalysis using AMS with trace (14)C-labeled drugs.
To provide perspectives on current applications and future opportunities for AMS in drug metabolism research.

Main Methods:

Utilizing Accelerator Mass Spectrometry (AMS) for the detection and quantification of (14)C-labeled drug metabolites.
Employing trace levels of (14)C-labeled drug candidates to minimize radioactivity exposure.
Developing and applying empirically based bioanalytical approaches for regulated studies.

Main Results:

AMS achieves attomole-level sensitivity, enabling matrix-independent quantitation of metabolites in small samples.
The technology significantly reduces the required radioactivity levels compared to traditional decay counting methods.
Early insights into human drug metabolism and disposition are now obtainable in ways previously impractical.

Conclusions:

Accelerator mass spectrometry overcomes the limitations of traditional (14)C detection, making it feasible for early and routine use in drug development.
Trace (14)C labeling combined with AMS offers a powerful tool for sensitive and cost-effective metabolite analysis.
This approach facilitates a deeper understanding of drug metabolism and disposition early in the clinical development process.